Predict your next investment

Venture Capital
oakwoodmedical.com

See what CB Insights has to offer

Investments

61

Portfolio Exits

14

Funds

4

About Oakwood Medical Investors

Oakwood Medical Investors is a life sciences venture capital fund formed to invest in development stage medical device, biopharmaceutical and healthcare service companies.

Oakwood Medical Investors Headquarters Location

10411 Clayton Road Suite 302

St. Louis, Missouri, 63131,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Oakwood Medical Investors News

EndoGastric Solutions rakes in $30 mln

May 8, 2014

Investors included Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, De Novo Ventures, Foundation Medical Partners, Oakwood Medical Investors and Radius Ventures. Based in San Mateo, Calif., EndoGastric Solutions develops products and procedures that treat gastrointestinal diseases. PRESS RELEASE SAN MATEO, Calif.–(BUSINESS WIRE)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced today that it completed raising $30 million in an internal round of financing. Existing investors including Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, De Novo Ventures, Foundation Medical Partners, Oakwood Medical Investors and Radius Ventures participated in the Series G financing round. “This is a pivotal time in the company’s evolution,” said Michael Carusi, EGS board member and General Partner of Advanced Technology Ventures. “The current management team is focused on a commercialization strategy that is balanced between investments in on-going product development, clinical data, healthcare economics and supporting trained physicians.” “The TIF procedure for reflux has the potential to help millions of patients that suffer from typical and atypical GERD symptoms,” said Skip Baldino, EGS President and CEO. “We are assisting professional societies in defining a clear pathway for reimbursement using the highest quality data from rigorous clinical trials.” With the recent investment, the Company intends to fund activities in support of publishing data from three randomized trials, bring new products to market, and establish clear reimbursement for its technology. About GERD Gastroesophageal Reflux Disease (GERD) is a condition caused by anatomical changes where the muscle at the base of the esophagus relaxes between swallows, allowing corrosive stomach acid to wash back up into the esophagus. The stomach produces hydrochloric acid after a meal to aid in the digestion of food. The cells that line the stomach consists of protective mucus that protect it from erosion, but the lining of the esophagus does not share these resistant features and stomach acid can damage it. GERD is the most common gastrointestinal-related diagnosis given by physicians during clinical visits in the U.S. It is estimated that pain and discomfort from acid reflux impacts over 23 million people two or more times per week in the U.S. The standard recommendations for symptomatic GERD patients include lifestyle changes (e.g. diet, scheduled eating times, and sleeping positions) and escalating doses of prescription medications for prolonged periods of time. Long-term, maximum dose usage of prescription medications has been linked to a variety of other health complications. Patients implement these recommendations trying to manage their symptoms and the quality of their lives becomes negatively impacted by these recommendations. About EsophyX® and Transoral Incisionless Fundoplication (TIF®) The EsophyX device was FDA cleared in 2007, and is commercially available in the United States. Inserted transorally with visual guidance from an endoscope, the EsophyX device is used in the TIF procedure to reconstruct the gastroesophageal valve (GEV), restoring its competency and reestablishing the barrier to reflux. The TIF procedure is a surgical solution that corrects the root cause of Gastroesophageal Reflux Disease (GERD). The TIF procedure is based on traditional surgical principles and offers similar effectiveness to a surgical repair with the safety profile of an incision-free approach. To date, more than 14,000 patients have been treated worldwide. For more information, visit www.GERDHelp.com. About EndoGastric Solutions® EndoGastric Solutions, Inc. (www.endogastricsolutions.com), headquartered in San Mateo, California, is a leader in the endoluminal treatment of digestive diseases. EGS’ mission is to combine the most advanced concepts in gastroenterology and surgery to develop products and procedures that address unmet needs in gastrointestinal diseases. Related Posts

Oakwood Medical Investors Investments

61 Investments

Oakwood Medical Investors has made 61 investments. Their latest investment was in Elira as part of their Series A - III on November 11, 2019.

CBI Logo

Oakwood Medical Investors Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/14/2019

Series A - III

Elira

$0.97M

No

1

4/29/2019

Series A

Keystone Bio

$5M

Yes

1

8/20/2018

Series A - II

Elira

$0.92M

No

1

9/14/2015

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

5/8/2015

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/14/2019

4/29/2019

8/20/2018

9/14/2015

5/8/2015

Round

Series A - III

Series A

Series A - II

Seed VC

Series D

Company

Elira

Keystone Bio

Elira

Subscribe to see more

Subscribe to see more

Amount

$0.97M

$5M

$0.92M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Oakwood Medical Investors Portfolio Exits

14 Portfolio Exits

Oakwood Medical Investors has 14 portfolio exits. Their latest portfolio exit was Broncus Medical on September 24, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/24/2021

IPO

$99M

Public

2

6/19/2015

Acquired

$99M

1

2/7/2014

IPO

$99M

Public

3

11/1/2013

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/28/2013

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/24/2021

6/19/2015

2/7/2014

11/1/2013

5/28/2013

Exit

IPO

Acquired

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

2

1

3

10

10

Oakwood Medical Investors Fund History

4 Fund Histories

Oakwood Medical Investors has 4 funds, including Oakwood Medical Investors IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2004

Oakwood Medical Investors IV

Multi-Stage Venture Capital

Closed

$43M

1

12/31/2001

Oakwood Medical Investors III

Subscribe to see more

Subscribe to see more

$99M

10

1/1/1999

Oakwood Medical Investors II

Subscribe to see more

Subscribe to see more

$99M

10

1/1/1997

Oakwood Investors I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2004

12/31/2001

1/1/1999

1/1/1997

Fund

Oakwood Medical Investors IV

Oakwood Medical Investors III

Oakwood Medical Investors II

Oakwood Investors I

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$43M

$99M

$99M

$99M

Sources

1

10

10

10

Oakwood Medical Investors Team

3 Team Members

Oakwood Medical Investors has 3 team members, including current Founder, President, Raul E. Perez.

Name

Work History

Title

Status

Raul E. Perez

Founder, President

Current

Daniel A. Burkhardt

Managing Director

Current

James L. Nouss

Managing Director

Current

Name

Raul E. Perez

Daniel A. Burkhardt

James L. Nouss

Work History

Title

Founder, President

Managing Director

Managing Director

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.